Sanofi-Aventis’ Taxotere Gains New Indication For Head And Neck Cancer
This article was originally published in The Pink Sheet Daily
Approval is based on data showing progression-free survival of 11.4 months.
You may also be interested in...
Taxotere promotional efforts regarding metastatic breast cancer use will be a "major field of activity during the months to come in the U.S.," Sanofi-Aventis Exec VP-Pharmaceutical Operations Hanspeter Spek said
Cetuximab was approved March 1 for treatment of advanced head and neck cancer.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.